Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens
Uložené v:
| Názov: | Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens |
|---|---|
| Autori: | Jesús Duque-Afonso, Paraschiva Rassner, Kristin Walther, Gabriele Ihorst, Claudia Wehr, Reinhard Marks, Ralph Wäsch, Hartmut Bertz, Thomas Köhler, Björn Christian Frye, Daiana Stolz, Robert Zeiser, Jürgen Finke, Kristina Maas-Bauer |
| Zdroj: | Bone Marrow Transplant |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2024. |
| Rok vydania: | 2024 |
| Predmety: | Male, Adult, Transplantation Conditioning, Incidence, Female [MeSH], Transplantation Conditioning/methods [MeSH], Adult [MeSH], Bronchiolitis Obliterans/etiology [MeSH], Humans [MeSH], Vidarabine/therapeutic use [MeSH], Vidarabine/adverse effects [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Risk Factors [MeSH], Hematopoietic Stem Cell Transplantation/adverse effects [MeSH], Busulfan/administration, Vidarabine/analogs, Male [MeSH], Transplantation Conditioning/adverse effects [MeSH], Graft vs Host Disease/etiology [MeSH], Busulfan/adverse effects [MeSH], Hematopoietic Stem Cell Transplantation/methods [MeSH], Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Middle Aged, Myeloablative Agonists, Article, Young Adult, Risk Factors, Humans, Transplantation, Homologous, Female, Bronchiolitis Obliterans, Busulfan, Cyclophosphamide, Vidarabine, Thiotepa, Retrospective Studies, Aged |
| Popis: | Bronchiolitis obliterans syndrome (BOS), as chronic manifestation of graft-versus-host disease (GVHD), is a debilitating complication leading to lung function deterioration in patients after allogeneic hematopoietic cell transplantation (allo-HCT). In the present study, we evaluated BOS development risk in patients after receiving myeloablative conditioning (MAC) regimens. We performed a retrospective analysis of patients undergoing allo-HCT, who received MAC with busulfan/cyclophosphamid (BuCy, n = 175) busulfan/fludarabin (FluBu4, n = 29) or thiotepa/busulfan/fludarabine (TBF MAC, n = 37). The prevalence of lung disease prior allo-HCT, smoking status, GvHD prophylaxis, HCT-CI score, EBMT risk score and GvHD incidence varied across the groups. The cumulative incidence of BOS using the NIH diagnosis consensus criteria at 2 years after allo-HCT was 8% in FluBu4, 23% in BuCy and 19% in TBF MAC (p = 0.07). In the multivariate analysis, we identified associated factors for time to BOS such as FEV1p = 0.004), CMV patient serology positivity (HR = 2.11, p = 0.014), TLC p = 0.02) and GvHD prophylaxis with in vivo T-cell depletion (HR = 0.29, p = 0.001) as predictors of BOS. In summary, we identified risk factors for BOS development in patients receiving MAC conditioning. These findings might serve to identify patients at risk, who might benefit from closely monitoring or early therapeutic interventions. |
| Druh dokumentu: | Article Other literature type |
| Popis súboru: | |
| Jazyk: | English |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/s41409-024-02422-z |
| Prístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/39333758 https://repository.publisso.de/resource/frl:6493352 |
| Rights: | CC BY |
| Prístupové číslo: | edsair.doi.dedup.....8b200c133b74fe53598d49d40d23b620 |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Bronchiolitis obliterans syndrome (BOS), as chronic manifestation of graft-versus-host disease (GVHD), is a debilitating complication leading to lung function deterioration in patients after allogeneic hematopoietic cell transplantation (allo-HCT). In the present study, we evaluated BOS development risk in patients after receiving myeloablative conditioning (MAC) regimens. We performed a retrospective analysis of patients undergoing allo-HCT, who received MAC with busulfan/cyclophosphamid (BuCy, n = 175) busulfan/fludarabin (FluBu4, n = 29) or thiotepa/busulfan/fludarabine (TBF MAC, n = 37). The prevalence of lung disease prior allo-HCT, smoking status, GvHD prophylaxis, HCT-CI score, EBMT risk score and GvHD incidence varied across the groups. The cumulative incidence of BOS using the NIH diagnosis consensus criteria at 2 years after allo-HCT was 8% in FluBu4, 23% in BuCy and 19% in TBF MAC (p = 0.07). In the multivariate analysis, we identified associated factors for time to BOS such as FEV1p = 0.004), CMV patient serology positivity (HR = 2.11, p = 0.014), TLC p = 0.02) and GvHD prophylaxis with in vivo T-cell depletion (HR = 0.29, p = 0.001) as predictors of BOS. In summary, we identified risk factors for BOS development in patients receiving MAC conditioning. These findings might serve to identify patients at risk, who might benefit from closely monitoring or early therapeutic interventions. |
|---|---|
| ISSN: | 14765365 02683369 |
| DOI: | 10.1038/s41409-024-02422-z |